{
      "Rank": 225,
      "Acronym": [],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "\"ex-vivo\" expanded autologous mesenchymal stem cells fixed in allogenic bone tissue for spinal fusion",
            "Instrumented spinal fusion together with patient's bone iliac crest."
      ],
      "ArmGroupInterventionName": [
            "Biological: XCEL-MT-OSTEO-ALPHA",
            "Procedure: Standard treatment"
      ],
      "ArmGroupLabel": [
            "XCEL-MT-OSTEO-ALPHA",
            "Standard treatment"
      ],
      "ArmGroupType": [
            "Experimental",
            "Sham Comparator"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT01552707"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "The present prospective, randomized study, compares the spinal fusion obtained after instrumentation and the use of a biologic product (patient's mesenchymal cells obtained from his/her own bone marrow which will be fixed in human bone tissue form a donor), with the current procedure that consists in instrumented spinal fusion and the use of each patient's bone obtained from his/her iliac crest.\n\nThe working hypothesis proposes that the tissue engineering is a valid and useful technique to achieve bone regeneration, avoiding the need for obtaining patient's iliac crest and its associated morbidity."
      ],
      "BriefTitle": [
            "Safety Study of Mesenchymal Stem Cells and Spinal Fusion"
      ],
      "CentralContactEMail": [],
      "CentralContactName": [],
      "CentralContactPhone": [],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [],
      "CollaboratorClass": [
            "INDUSTRY",
            "OTHER_GOV",
            "OTHER_GOV"
      ],
      "CollaboratorName": [
            "TFS Trial Form Support",
            "Ministerio de Sanidad, Servicios Sociales e Igualdad",
            "Ministerio de Ciencia e Innovaci\u00f3n, Spain"
      ],
      "CompletionDate": [
            "October 21, 2019"
      ],
      "CompletionDateType": [
            "Actual"
      ],
      "Condition": [
            "Lumbar Spondylolisthesis Involving L4-L5, and/or",
            "Degenerative Discopathy Involving L4-L5"
      ],
      "ConditionAncestorId": [
            "D000013169",
            "D000055009",
            "D000013122",
            "D000001847",
            "D000009140"
      ],
      "ConditionAncestorTerm": [
            "Spondylolysis",
            "Spondylosis",
            "Spinal Diseases",
            "Bone Diseases",
            "Musculoskeletal Diseases"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC05",
            "All"
      ],
      "ConditionBrowseBranchName": [
            "Musculoskeletal Diseases",
            "All Conditions"
      ],
      "ConditionBrowseLeafAsFound": [
            "Spondylolisthesis"
      ],
      "ConditionBrowseLeafId": [
            "M15115",
            "M15116",
            "M27146",
            "M15071",
            "M4278",
            "M11249"
      ],
      "ConditionBrowseLeafName": [
            "Spondylolisthesis",
            "Spondylolysis",
            "Spondylosis",
            "Spinal Diseases",
            "Bone Diseases",
            "Musculoskeletal Diseases"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "low",
            "low",
            "low",
            "low",
            "low"
      ],
      "ConditionMeshId": [
            "D000013168"
      ],
      "ConditionMeshTerm": [
            "Spondylolisthesis"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "Randomized"
      ],
      "DesignInterventionModel": [
            "Parallel Assignment"
      ],
      "DesignInterventionModelDescription": [],
      "DesignMasking": [
            "None (Open Label)"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [],
      "DetailedDescription": [
            "Prospective, open-label, randomized, parallel, single-dose phase I-II clinical trial in which 62 patients affected with L4-L5 degenerative spondylolisthesis grade I-II according to Meyerding and/or with L4-L5 degenerative discopathy needing spinal fusion will enter the trial with the primary objective of assessing the feasibility and safety of \"ex-vivo\" expanded autologous mesenchymal stem cells fixed in allogenic bone tissue in spinal fusion. Secondary objectives are to assess the efficacy of the implantation by imaging (computerized helicoidal tomography and X-ray) and clinical questionnaires (pain by visual analogue scale, quality of life by SF-36 and Oswestry Disability Index).\n\nPatients will be randomized to one of the two treatment arms (instrumented spinal fusion and the tissue engineering product composed by \"ex-vivo\" expanded autologous mesenchymal stem cells fixed in allogenic bone tissue in spinal fusion or the standard treatment of instrumented spinal fusion and patient's bone iliac crest). Thereafter, patients will be followed for 12 months.\n\nImaging assessment will be done by an independent blinded radiologist."
      ],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nL4-L5 degenerative spondylolisthesis grade I-II Meyerding isolated or associated to more than one level, and/or L4-L5 degenerative discopathy isolated or associated to more than one level.\n18 to 85 years of age (male and female)\nInformed Consent Form signed\nThe patient is able to understand the nature of the study\n\nExclusion Criteria:\n\nPrevious spine surgery\nL4 isthmic spondylolisthesis\nSmoker (more than 10 cigarettes a day)\nSystemic or local infection\nPatients treated with steroids (oral or systemic) within 3 months of entering the study, or treated with biphosphonates for more than 10 years\nPositive serology for HIV-1 or HIV-2, Hepatitis B (HBsAg), Hepatitis C (Anti-HCV-Ab) or Syphilis.\nPregnant woman or intended to become pregnant, or breath feeding\nNeoplasia within the previous 5 years, or without remission\nImmunosuppressive states (except diabetes mellitus. Treatment with therapies is allowed)\nSignificant abnormal laboratory tests that contraindicates the surgery.\nParticipation in another clinical trial or treated with an investigational medicinal product the previous 3 months\nOther pathologic conditions or circumstances that difficult participation in the study according to medical criteria\nThe patient does not accept to be followed-up for a period that could exceed the clinical trial length\nThe patient is legally dependent"
      ],
      "EnrollmentCount": [
            "69"
      ],
      "EnrollmentType": [
            "Actual"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [],
      "InterventionAncestorTerm": [],
      "InterventionArmGroupLabel": [
            "XCEL-MT-OSTEO-ALPHA",
            "Standard treatment"
      ],
      "InterventionBrowseBranchAbbrev": [],
      "InterventionBrowseBranchName": [],
      "InterventionBrowseLeafAsFound": [],
      "InterventionBrowseLeafId": [],
      "InterventionBrowseLeafName": [],
      "InterventionBrowseLeafRelevance": [],
      "InterventionDescription": [
            "Isolation and \"ex-vivo\" expansion of mesenchymal stem cells (MSC) obtained from each patient's bone marrow under GMP conditions at Xcelia, Divisi\u00f3n de Terapias Avanzadas delBanc de Sang i Teixits. After expansion, MSCs are fixed in allogenic bone tissue and implanted in instrumented spinal fusion.",
            "Instrumented spinal fusion together with patient's bone iliac crest"
      ],
      "InterventionMeshId": [],
      "InterventionMeshTerm": [],
      "InterventionName": [
            "XCEL-MT-OSTEO-ALPHA",
            "Standard treatment"
      ],
      "InterventionOtherName": [],
      "InterventionType": [
            "Biological",
            "Procedure"
      ],
      "IsFDARegulatedDevice": [],
      "IsFDARegulatedDrug": [],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [
            "Spondylolisthesis",
            "Degenerative discopathy",
            "Mesenchymal Stem Cells",
            "Bone marrow",
            "Tissue engineering",
            "Spinal fusion"
      ],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [],
      "LastUpdatePostDate": [
            "January 21, 2020"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "January 15, 2020"
      ],
      "LeadSponsorClass": [
            "OTHER"
      ],
      "LeadSponsorName": [
            "Banc de Sang i Teixits"
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Badalona",
            "Barcelona",
            "Barcelona",
            "Barcelona",
            "Barcelona"
      ],
      "LocationContactEMail": [],
      "LocationContactName": [],
      "LocationContactPhone": [],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [],
      "LocationCountry": [
            "Spain",
            "Spain",
            "Spain",
            "Spain",
            "Spain"
      ],
      "LocationFacility": [
            "Hospital Universitari Germans Trias i Pujol",
            "Parc de Salut Mar",
            "Hospital de la Santa Creu i Sant Pau",
            "Institut Universitari Dexeus (ICATME)",
            "Hospital Vall d'Hebron"
      ],
      "LocationState": [
            "Barcelona"
      ],
      "LocationStatus": [],
      "LocationZip": [
            "08916",
            "08003",
            "08025",
            "08028",
            "08035"
      ],
      "MaximumAge": [
            "85 Years"
      ],
      "MinimumAge": [
            "18 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "\"Ex Vivo\" Expanded Autologous Bone Marrow Mesenchymal Stem Cells Fixed in Allogenic Human Bone Tissue for Spinal Fusion in Spine Degenerative Disease"
      ],
      "OrgClass": [
            "OTHER"
      ],
      "OrgFullName": [
            "Banc de Sang i Teixits"
      ],
      "OrgStudyId": [
            "XCEL-MT-10-02"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [
            "Hospital Vall d'Hebron"
      ],
      "OverallOfficialName": [
            "Joan Bag\u00f3, MD, PhD"
      ],
      "OverallOfficialRole": [
            "Principal Investigator"
      ],
      "OverallStatus": [
            "Completed"
      ],
      "OversightHasDMC": [
            "No"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Phase 1",
            "Phase 2"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "May 3, 2018"
      ],
      "PrimaryCompletionDateType": [
            "Actual"
      ],
      "PrimaryOutcomeDescription": [
            "Safety will be assessed by collecting adverse events throughout the experimental phase, which includes a follow-up of 12 months",
            "Feasibility will be measured by assessing the percentage of patients to which bone marrow puncture is made are thereafter treated and by checking the cascade of procedures to confirm the global process is viable."
      ],
      "PrimaryOutcomeMeasure": [
            "safety of XCEL-MT-OSTEO-ALPHA (tissue engineering product composed by \"ex-vivo\" expanded autologous mesenchymal stem cells fixed in allogenic bone tissue in spinal fusion)",
            "Feasibility of XCEL-MT-OSTEO-ALPHA (composed by \"ex-vivo\" expanded autologous mesenchymal stem cells fixed in allogenic bone tissue in spinal fusion)"
      ],
      "PrimaryOutcomeTimeFrame": [
            "12 months",
            "12 months"
      ],
      "ReferenceCitation": [
            "Vives J, Oliver-Vila I, Pla A. Quality compliance in the shift from cell transplantation to cell therapy in non-pharma environments. Cytotherapy. 2015 Aug;17(8):1009-14. doi: 10.1016/j.jcyt.2015.02.002. Epub 2015 Mar 10. Review."
      ],
      "ReferencePMID": [
            "25769789"
      ],
      "ReferenceType": [
            "derived"
      ],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [],
      "ResponsiblePartyInvestigatorFullName": [],
      "ResponsiblePartyInvestigatorTitle": [],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Sponsor"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [],
      "SecondaryOutcomeDescription": [
            "Spinal fusion will be assessed by spinal X-Ray",
            "Spinal fusion will be assessed by the presence of solid bonny bridges using computerized helicoidal tomography.",
            "Pain measurement by visual analogue scale (VAS)",
            "This clinical outcome will measure the quality of life by the self-reported quality of life questionnaire SF-36",
            "To assess the extent by which a person's functional level is restricted by disability by the Oswestry Disability Index"
      ],
      "SecondaryOutcomeMeasure": [
            "Efficacy spinal fusion by imaging procedures (X-Ray).",
            "Efficacy spinal fusion by imaging procedures (computerized helicoidal tomography)",
            "Clinical outcomes (VAS)",
            "Clinical outcomes (SF-36)",
            "Clinical outcome (Oswestry Disability Index)"
      ],
      "SecondaryOutcomeTimeFrame": [
            "3, 6 and 12 months",
            "6 and 12 months",
            "7 days and at 3, 6 and 12 months",
            "3, 6 and 12 months",
            "3, 6 and 12 months"
      ],
      "SeeAlsoLinkLabel": [
            "Banc de Sang i Teixits. Xcelia, Divisi\u00f3n de Terapias Avanzadas.",
            "Institut Catal\u00e0 de Traumatologia i Medicina de l'Esport (Institut Universitari Dexeus)",
            "Hospital Universitari Vall d'Hebron, Barcelona",
            "Hospital Universitari Germans Trias i Pujol, Badalona",
            "Hospital Parc de Salut Mar, Barcelona",
            "Hospital de la Santa Creu i Sant Pau, Barcelona"
      ],
      "SeeAlsoLinkURL": [
            "http://www.bancsang.net",
            "http://www.icatme.com",
            "http://www.vhebron.net",
            "http://www.gencat.cat/ics/germanstrias/",
            "http://www.parcdesalutmar.cat",
            "http://www.santpau.es/"
      ],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "July 19, 2012"
      ],
      "StartDateType": [
            "Actual"
      ],
      "StatusVerifiedDate": [
            "January 2020"
      ],
      "StdAge": [
            "Adult",
            "Older Adult"
      ],
      "StudyFirstPostDate": [
            "March 13, 2012"
      ],
      "StudyFirstPostDateType": [
            "Estimate"
      ],
      "StudyFirstSubmitDate": [
            "March 8, 2012"
      ],
      "StudyFirstSubmitQCDate": [
            "March 8, 2012"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 10, 2022"
      ],
      "WhyStopped": []
}